#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
This in vitro and clinical study examines potential drug interactions between THC and diclofenac, a commonly used nonsteroidal anti-inflammatory drug, relevant for patients who may use cannabis concurrently with standard pain management regimens. The research demonstrates that cannabis extracts containing THC can inhibit cytochrome P450 enzymes responsible for diclofenac metabolism, with a crossover clinical study in healthy adults confirming measurable pharmacokinetic changes when oral THC is administered alongside diclofenac. These findings suggest that THC may increase diclofenac bioavailability and potentially elevate systemic exposure to the NSAID, which could heighten risks of adverse effects including gastrointestinal complications and renal toxicity in vulnerable populations. Clinicians prescribing diclofenac or other NSAIDs to cannabis users should be aware of this interaction and consider dose adjustments or alternative pain management strategies when concurrent use is necessary. Patients using both medications should be counseled about potential increased NSAID side effects and monitored appropriately for tolerability. This interaction highlights the importance of comprehensive medication reconciliation and patient communication regarding cannabis use in clinical practice.
💊 The potential interaction between THC and diclofenac warrants clinical attention, particularly as patients increasingly use cannabis for pain management alongside nonsteroidal anti-inflammatory drugs. While in vitro studies suggest possible pharmacokinetic interactions through shared metabolic pathways, the limited clinical evidence from human studies remains inconclusive about the magnitude and clinical significance of such interactions in real-world settings. Important confounders including individual variation in cannabinoid metabolism, the wide range of THC dosing and formulations available, concurrent medications, and the heterogeneity of patient populations studied make it difficult to generalize findings to typical clinical practice. Healthcare providers should remain alert to this potential interaction when patients concurrently use THC and diclofenac, monitoring for changes in efficacy or adverse effects, and consider counseling patients about this possible drug interaction until more robust clinical evidence emerges. A pragmatic approach involves documenting concurrent use, asking about
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
